Ayala Pharmaceuticals Inc (ADXS)

[blueyedcatch]

Easy now,let`s see if the CMO is worth his salary before blaming Ken for this.No one can totally predict what the FDA will ask for. This seems fair,considering that Adxs is looking to change the trial design,for an already enrolling and running trial. The FDA has to make itself look efficient in handling the safety of patients for trials. Hey FDA we want to make our AIM2CERV trial shorter,to get an earlier data read,and we want to change the strength and dosage of trial design to accomplish that. The FDA has to check this all out thoroughly,before letting Adxs do this. Standard protocol,if you ask this investor.